Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793739 | 0.96 | CPB2 (0.46) | GSRCPB2RNPEPFOLH1SLC6A5 | |
| SCHEMBL657408 | 0.88 | GABRR1 (0.45) | GSRCPB2RNPEPFOLH1SLC6A5 | |
| Hydrochloric Acid SCHEMBL1026854 | 0.86 | GABRR1 (0.43) | GSRCPB2RNPEPFOLH1SLC6A5 | |
| SCHEMBL28449984 | 0.85 | GSR (0.39) | GSRCPB2RNPEPFOLH1DPP8 | |
| SCHEMBL9995723 | 0.85 | MMP3 (0.39) | GSRCPB2 | |
| SCHEMBL3659774 | 0.83 | PRSS1 (0.35) | GSRCPB2FOLH1 | |
| SCHEMBL29029802 | 0.82 | CA2 (0.50) | — | |
| SCHEMBL4070665 | 0.82 | MMP1 (0.34) | — | |
| SCHEMBL3647951 | 0.81 | MEN1 (0.32) | — | |
| SCHEMBL333214 | 0.81 | MEN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017637-B2 | Inhibitors of cdc phosphatases | IPSEN PHARMA S.A.S. (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-11-05 | — | — | US | disclosed |
| EP-1831209-B1 | CDC25 PHOSPHATASE INHIBITORS | IPSEN PHARMA (FR) | 2009-08-12 | — | — | EP | disclosed |
| EP-1793825-A2 | CHEMCIAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006036816-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | CDC25C, CDC25A, CDC25B | GSR 3924/4885CPB2 1885/4885RNPEP 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.